DelMar Pharmaceuticals Hosts Symposium at International Brain Tumor Meeting
Seminar at the Chinese Society for NeuroOncology Highlights Opportunities to Expand Development of VAL-083 Into Front-line GBM Therapy
VANCOUVER, BC and MENLO PARK, CA -- (Marketwired) -- 08/12/13 -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company hosted a symposium entitled "VAL-083 for Newly Diagnosed GBM Patients with Unmethylated MGMT Promoter" at the 10th Annual Meeting of the Chinese Society for NeuroOncology (CSNO), in Kunming, China on August 10, 2013.
The DelMar session, which was led by Professor ZongPing Chen, chair of the Chinese Society for NeuroOncology, brought together more than 40 leading Chinese neurosurgeons and oncologists to discuss VAL-083 as a potential front-line therapy for glioblastoma patients whose tumors feature high expression of MGMT, a repair enzyme that makes the cancer unlikely to respond to Temodar®, the current standard-of-care. During the session, Dr. Kent Shih presented an overview of VAL-083, a rationale for front-line therapy, and a proposed front-line trial design for discussion among the symposium attendees and DelMar management.
Dr. Shih is a clinical oncologist and a lead investigator in DelMar's ongoing clinical trial for refractory glioblastoma in the United States. Dr. Shih's presentation at the CSNO meeting highlighted the following: 1) the unique mechanism of VAL-083; 2) the drug's activity against newly diagnosed GBM based on published literature from historical clinical trials, and; 3) the recent promising results of DelMar's ongoing clinical trial in refractory GBM.
DelMar is currently conducting a Phase I/II dose-escalation study designed to assess the safety and efficacy of VAL-083 as a potential treatment for brain cancer patients suffering from glioblastoma multiforme (GBM) and secondary brain tumors who have failed standard therapies and have no viable treatment options.
Jeffrey Bacha, DelMar's president & CEO said, "We were very pleased to have this opportunity to introduce our rationale for commencing a clinical trial in newly-diagnosed GBM at this year's CSNO meeting. We plan to work closely with our clinical advisors to design and initiate this trial, which could potentially provide a new treatment option for patients who have been newly diagnosed with glioblastoma and have been identified as unlikely to respond to the current standard of care."
VAL-083 is currently approved in China for the treatment of chronic myelogenous leukemia and lung cancer. DelMar has established a collaboration and exclusive supply agreement with Guangxi Wuzhou Pharmaceuticals, the only company licensed by the Chinese Food and Drug Administration to manufacture VAL-083 as a cancer therapy. Under the terms of the collaboration, DelMar and Guangxi Wuzhou Pharmaceuticals are working together to ensure the product specifications meet global standards in order to accelerate international development and regulatory approval for VAL-083 on a worldwide basis. Guangxi Wuzhou Pharmaceuticals will provide funding for clinical trials conducted in China and will be the exclusive supplier of DAG for injection and DelMar will be responsible for development and commercialization. DelMar is currently seeking to establish a separate collaboration for the distribution, sales and marketing of VAL-083 in China.
VAL-083 represents a 'first-in-class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI-sponsored clinical studies in various cancers including lung, brain, cervical, ovarian tumors and leukemia. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.
Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent; however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents used in the treatment of GBM.
VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies. Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as 06-methylguanine methyltransferase (MGMT), may not confer resistance to VAL-083.
VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma. Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.
VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors. In general, tumor regression was achieved following therapy in greater than 40 percent of patients treated and stabilization was achieved in an additional 20 to 30 percent. In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high-grade gliomas when combined with radiation versus radiation alone.
The main dose-limiting toxicity related to the administration of VAL-083 in previous clinical studies was myelosuppression. No significant hepatic, renal or pulmonary toxicity has been reported in the literature or overseas commercial experience.
About Glioblastoma Multiforme (GBM)
GBM is the most common and most malignant form of brain cancer. Of the estimated 17,000 primary brain tumors diagnosed in the U.S. each year, approximately 60 percent are gliomas. Attention was drawn to this form of brain cancer when Senator Ted Kennedy was diagnosed with glioblastoma in 2008 and ultimately died from the disease fifteen months later.
Newly diagnosed patients suffering from GBM are initially treated through invasive brain surgery, although disease progression following surgical resection is nearly 100 percent. Temodar in combination with radiation is the front-line therapy for GBM following surgery. Temodar currently generates more than US$950 million annually in global revenues primarily from the treatment of brain cancer.
Approximately 60 percent of GBM patients treated with Temodar experience tumor progression within one year. Avastin® has been approved for the treatment of GBM in patients failing Temodar. According to the Avastin® label, approximately 20 percent of patients failing Temodar respond to Avastin® therapy. Analysts anticipate annual Avastin revenues for the treatment of brain cancer may reach US$650 million by 2016.
Approximately 48 percent of patients who are diagnosed with GBM will fail both front-line Temodar therapy and Avastin. DelMar estimates that the market for treating GBM patients the post-Avastin failure exceeds US$200 million annually in North America.
About the VAL-083 Clinical Trial
The ongoing Phase I/II study is an open-label, single arm dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of VAL-083 in patients with histologically confirmed initial diagnosis of primary WHO Grade IV malignant glioma (GBM), now recurrent. Patients with prior low-grade glioma or anaplastic glioma are eligible, if histologic assessment demonstrates transformation to GBM.
GBM patients must have been previously treated for GBM with surgery and/or radiation, if appropriate, and must have failed both Avastin and Temodar, unless either or both are contra-indicated.
Response to therapy and disease progression will be evaluated by MRI prior to each treatment cycle. An initial phase of the study will involve dose escalation cohorts until a maximum tolerated dose (MTD) is established in the context of modern care. Once the modernized dosing regimen has been established, additional patients will be enrolled at the MTD (or other selected optimum dosing regimen).
DelMar is conducting the study at three clinical sites including the University of California, San Francisco, the Sarah Cannon Research Institute in Nashville, Tennessee and at the Florida Cancer Specialists & Research Institute in Sarasota, Florida.
Please refer to clinicaltrials.gov identifier NCT01478178 for further details on this clinical trial or visit: http://www.clinicaltrials.gov/ct2/show/NCT01478178?term=VAL--083&rank=1
About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
For further information, please visit www.delmarpharma.com; or contact Jeffrey A. Bacha, President & CEO (604) 629-5989 or Booke & Company Investor Relations, email@example.com
For further information, please visit www.delmarpharma.com;
Jeffrey A. Bacha
President & CEO
or Booke & Company Investor Relations
Source: DelMar Pharmaceuticals, Inc.
Released August 12, 2013